DEERFIELD, Ill.--(BUSINESS WIRE)--Dade Behring Inc. (NASDAQ:DADE) today announced that it has signed a license agreement with Radboud University Nijmegen Medical Centre (RUNMC) granting Dade Behring with the exclusive rights for a new coagulation test called the Nijmegen Hemostasis Assay (NHA), anticipated by researchers at RUNMC to become accepted for testing a broad range of coagulation disorders. A research agreement was also signed granting Dade Behring with the rights to results from future NHA research and development performed by RUNMC.
